PLACE OF DIBCOR® IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AND METABOLIC SYNDROME


Дәйексөз келтіру

Толық мәтін

Аннотация

The article is dedicated to the role of taurine in the human body, the possibility of therapeutic use of Dibicor ®, a taurine-based drug, including diabetic patients. The results of use of Dibicor ® in the complex therapy of patients with type 2 diabetes mellitus (DM2) and metabolic syndrome (MS) are presented. Study involving 40 patients has shown that inclusion of Dibicor ® at a dose of 0.5 g 2 times daily in the treatment regimen has contributed to the decline in body mass index, lower waist and hips circumferences and improvement of carbohydrate and lipid metabolism (significant reduction in glycated hemoglobin, fasting glucose, total cholesterol, triglyceride and low density lipoprotein cholesterol levels) in patients with DM2 and MS.

Авторлар туралы

Natal'ya Vorokhobina

Alla Kuznetsova

N Vorohobina

A Kuznetsova

Әдебиет тізімі

  1. Wild S, et al. Diabetes Care 2004;27:1047-53
  2. UKPDS 33. Lancet 1998;352:837-53
  3. American Diabetes Association. Diabetes Care 2003;26(1):83-86
  4. Крючкова И.В., Адамчик А.С. Возможности коррекции нарушений углеводного обмена при метаболическом синдроме // Российский кардиологический журнал. 2009. Т. 76. № 2. С. 44-45.
  5. Недосугова Л.В. Место дибикора в комплексной терапии сахарного диабета // Фарматека 2008. № 17. С. 22-23.
  6. Елизарова Е.П. Применение Дибикора в кардиологической практике: Пособие для врачей. М., 2005.
  7. Nakagawa K. Effect of taurine on alteration in adrenal functions induced by stress. Jap J Pharmacol 1975;25:737-46.
  8. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ 2000;321:405-12.
  9. Palmi M, Youmbi GT, Fusi F, et al. Potentiation of mitochondrial Ca2+ sequestration by taurine. Biochem Pharmacol 1999;58(7):1123-31.
  10. El Idrissi A, Trenkner E. Taurine as a modulator of excitatory and inhibitory neurotransmission. Neurochem Res 2004;29(1):189-97.
  11. Bustamante J, Lobo MV, Alonso FJ, et al. An osmotic-sensitive taurine pool is localized in rat pancreatic islet cells containing glucagon and somatostatin. Am J Physiol Endocrinol Metab 2001;281(6):E1275-85.
  12. Huxtable RJ. Physiological actions of taurine. Physiol Rev 1992;72(1):101-63.
  13. Lampson WG, Kramer JH, Schaffer SW. Potentiation of the actions of insulin by taurine. Can J Physiol Pharmacol 1983;61(5):457-63.
  14. Askerman D, Heisen HA. J Physiol Chem 1935;235:115-21.
  15. Докшина Г.А., Силаева Т.Ю., Ярцев Е.И. Некоторые инсулиноподобные эффекты таурина // Вопросы медицинской химии 1976. № 22. С. 503-507.
  16. Maturo J, Kulakowsky EC. Insulin-like activeity of taurine. In; The biology of taurine:methods and mechanisms. Huxtable RJ, Fanconi F, Giotti A. (eds). Plenum Press, New York 1987:217-26.
  17. Lampson WG, Kramer JN, Schafter SW. Potentiation of the actions of insulin by taurine. Can J Physiol Pharmacol 1983;61:457-63.
  18. Franconi, et al. Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: effects of taurine supplementation. Am J Clin Nutr 1995;61:1115-19.
  19. Wu QD, Wang JH, Fennessy F, Redmond HP. Taurine prevents high-glucose-induced human vascular endothelial cell apoptosis. Am J Physiol 1999;277(6 Pt 1):1229-38.
  20. Hansen SH, Andersen ML, Birkedal H, Cornett C, Wibrand F. The impotant role of taurine in oxidative metabolism. Adv Exp Med Biol 2006;583:129-35.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2012